It is clear now that SARS-CoV-2 could use angiotensin-converting enzyme 2 (ACE2), the same receptor as SARS-CoV Transmembrane protease serine type 2 (TMPRSS2), a protease belonging to the type II transmembrane serine protease family, cleaves the coronavirus spike protein Serine proteases are inhibited by a diverse group of inhibitors, The best-studied serpins are antithrombin and alpha 1-antitrypsin

Start Date01 Jun 2020

Sponsor / Collaborator-

NCT01684410 / CompletedPhase 2

A Three Week Dose Escalation, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of 100 mg or 200 mg of Inhaled Alpha-1 HC, Once a Day in Subjects With Cystic Fibrosis.

This was a randomized, double-blind, placebo-controlled, dose escalation study to assess the safety and tolerability of 100 mg and 200 mg of inhaled Alpha-1 HC administered once a day for three weeks in subjects aged 18 years and older with cystic fibrosis (CF). The treatment duration in this study was intended to provide multi-dose safety information prior to proceeding to longer durations of exposure.

Start Date01 Aug 2012

Sponsor / Collaborator

Grifols Therapeutics, Inc.

100 Clinical Results associated with Alpha-1-antitrypsin inhalation(Bayer AG)

100 Translational Medicine associated with Alpha-1-antitrypsin inhalation(Bayer AG)

100 Patents (Medical) associated with Alpha-1-antitrypsin inhalation(Bayer AG)

Literatures (Medical) associated with Alpha-1-antitrypsin inhalation(Bayer AG)

01 Mar 2016·Journal of Cystic FibrosisQ2 · MEDICINE

Inhaled alpha 1 -proteinase inhibitor therapy in patients with cystic fibrosis

Q2 · MEDICINE

Article

Author: Griffin, Rhonda ; Flume, Patrick A ; Gaggar, Amit ; Chen, Junliang ; Donaldson, Scott H ; Nichols, David ; Chmiel, James F ; Dorkin, Henry L

BACKGROUNDInhaled alpha1-proteinase inhibitor (PI) is known to reduce neutrophil elastase burden in some patients with CF. This phase 2a study was designed to test inhaled Alpha-1 HC, a new aerosolized alpha1-PI formulation, in CF patients.METHODSWe performed a randomized, double-blind, placebo-controlled study and evaluated the safety of 100 or 200mg of inhaled Alpha-1 HC once daily for 3 weeks in subjects with CF. Thirty adult subjects were randomized in a 2:1 ratio to receive Alpha-1 HC or placebo.RESULTSDrug delivery was confirmed by a dose-dependent increase in the sputum alpha1-PI. Seven (20.0%) of the 35 adverse events in the 100-mg dose group, 3 (13.0%) of 23 in the 200-mg dose group, and 4 (14.3%) of 28 in the placebo group were drug-related in these subjects. One serious adverse event occurred in 1 subject within each group.CONCLUSIONSAlpha-1 HC inhalation was safe and well tolerated.

15 May 1990·CancerQ1 · MEDICINE

Reduced hematologic response to alpha-interferon therapy in patients with hairy cell leukemia showing a peculiar immunologic phenotype

Q1 · MEDICINE

Article

Author: D. Raspadori ; P. L. Zinzani ; S. Tura ; L. Gugliotta ; R. Foa ; F. Lauria ; S. Macchi ; M. Buzzi

Alpha-interferon (alpha-IFN) treatment is highly effective in normalizing the clinical, hematologic, and immunologic parameters of patients with hairy cell leukemia (HCL). Complete remissions (CR), however, are rare, and a few patients do not respond adequately to alpha-IFN. That the poor response to alpha-IFN treatment could be related to a particular immunologic surface marker profile of the HC was investigated in this study. The results showed that most patients who do not respond adequately to alpha-IFN HC have a peculiar immunologic phenotype with a positive response to the Leu1 (CD5) monoclonal antibody, usually absent on HC but characteristically expressed on B-chronic lymphocytic leukemia cells. Of nine HCL patients with this phenotype, only three had partial remissions (PR) and six minor responses (MR) compared with the three CR, 16 PR, and three MR observed in the 22 Leu1 (CD5)-negative patients. The authors postulate that a more extensive immunologic analysis of HCL patients at diagnosis may be predictive of the response to IFN treatment.

100 Deals associated with Alpha-1-antitrypsin inhalation(Bayer AG)

External Link

KEGG	Wiki	ATC	Drug Bank
-	Alpha-1-antitrypsin inhalation(Bayer AG)	-	DB05481

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cystic Fibrosis	Phase 2	-	Vectura Group Ltd.	-
Cystic Fibrosis	Phase 2	-	Bayer AG	-
Cystic Fibrosis	Phase 2	-	Bayer AG	-
Cystic Fibrosis	Phase 2	-	Vectura Group Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01684410 (CTgov)	Phase 2	Cystic Fibrosis	30	Alpha-1 HC 100 mg (Alpha-1 HC 100 mg)	ncxatemqoq(bisymnnbed) = fzdeodqjzo xzwcktmfnu (seyignkizf, dxjqrwbxww - rflgscrnhx) View more	-	08 Feb 2016
				Alpha-1 HC 200 mg (Alpha-1 HC 200 mg)	ncxatemqoq(bisymnnbed) = xkqetkbdom xzwcktmfnu (seyignkizf, bbhyclfids - zqcqsbzwjy) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Alpha-1-antitrypsin inhalation(Bayer AG)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation